A business in context

PTHS research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-02 · 0001919246-26-000131

  2. 4 · Ownership change

    Report date 2026-10-02 · 0001919246-26-000130

  3. 4 · Ownership change

    Report date 2026-10-02 · 0001919246-26-000129

  4. 8-K · Current report

    Report date 2026-09-29 · 0001919246-26-000125 · Items 5.02,5.07,9.01

  5. DEF 14A · Proxy statement

    Report date 2026-09-29 · 0001919246-26-000120

  6. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001919246-26-000113

  7. 8-K · Current report

    Report date 2026-08-13 · 0001919246-26-000112 · Items 2.02,7.01,9.01

  8. 10-Q/A · Quarterly report

    Report date 2026-03-31 · 0001919246-26-000111

  9. 8-K · Current report

    Report date 2026-08-12 · 0001919246-26-000110 · Items 4.02

  10. 4 · Ownership change

    Report date 2026-07-02 · 0001919246-26-000102

  11. 4 · Ownership change

    Report date 2026-07-02 · 0001919246-26-000101

  12. 4 · Ownership change

    Report date 2026-07-02 · 0001919246-26-000100

  13. 4 · Ownership change

    Report date 2026-06-15 · 0001919246-26-000093

  14. 4 · Ownership change

    Report date 2026-06-11 · 0001919246-26-000088

  15. 8-K · Current report

    Report date 2026-05-28 · 0001919246-26-000085 · Items 7.01,9.01

  16. 8-K · Current report

    Report date 2026-05-15 · 0001919246-26-000078 · Items 4.01,5.02,9.01

  17. 8-K · Current report

    Report date 2026-05-14 · 0001919246-26-000071 · Items 2.02,7.01,9.01

  18. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001919246-26-000070

  19. 8-K · Current report

    Report date 2026-04-14 · 0001919246-26-000060 · Items 7.01,9.01

  20. 8-K · Current report

    Report date 2026-04-10 · 0001919246-26-000058 · Items 5.02,7.01,9.01

  21. 8-K · Current report

    Report date 2026-03-19 · 0001919246-26-000014 · Items 2.02,7.01,9.01

  22. 10-K · Annual report

    Report date 2025-12-31 · 0001919246-26-000013

  23. 8-K · Current report

    Report date 2026-01-12 · 0001753926-26-000097 · Items 1.01,2.03,3.02,7.01,9.01

  24. 8-K · Current report

    Report date 2026-01-06 · 0001753926-26-000094 · Items 5.02,7.01

  25. 8-K · Current report

    Report date 2025-12-23 · 0001753926-26-000010 · Items 1.01,8.01,9.01

  26. 8-K · Current report

    Report date 2025-12-23 · 0001753926-25-001964 · Items 5.02,8.01,9.01

  27. 8-K · Current report

    Report date 2025-12-17 · 0001753926-25-001906 · Items 5.07

  28. DEF 14A · Proxy statement

    Report date 2025-12-17 · 0001753926-25-001827

  29. 8-K · Current report

    Report date 2025-11-13 · 0001753926-25-001766 · Items 2.02,7.01,9.01

  30. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001753926-25-001764

  31. 8-K · Current report

    Report date 2025-11-07 · 0001753926-25-001715 · Items 1.01,2.03,3.02,8.01,9.01

  32. 8-K · Current report

    Report date 2025-10-14 · 0001753926-25-001606 · Items 7.01

  33. 8-K/A · Current report

    Report date 2025-09-16 · 0001753926-25-001500 · Items 2.01,2.02,9.01

  34. 8-K · Current report

    Report date 2025-09-02 · 0001753926-25-001425 · Items 7.01,9.01

  35. 8-K · Current report

    Report date 2025-08-18 · 0001753926-25-001353 · Items 2.02,7.01,9.01

  36. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001753926-25-001326

  37. 8-K · Current report

    Report date 2025-07-01 · 0001753926-25-001055 · Items 1.01,2.01,2.03,3.02,3.03,5.01,5.02,5.03,8.01,9.01

  38. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001753926-25-000790

  39. 8-K · Current report

    Report date 2025-05-01 · 0001753926-25-000722 · Items 7.01,9.01

  40. 8-K · Current report

    Report date 2025-04-17 · 0001753926-25-000652 · Items 1.01,3.02,4.01,5.07,7.01,8.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 6 transaction rows6SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

6 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-07-02
2026-07-07
Friedberg Ezra M
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock534.026.03
2026-07-02
2026-07-07
Friedberg Ezra M
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock24.027.33
2026-07-02
2026-07-07
Pauls Matthew
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock94.027.36
2026-07-02
2026-07-07
Pauls Matthew
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock692.026.0
2026-07-02
2026-07-07
Greenleaf Peter
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock712.026.0
2026-07-02
2026-07-07
Greenleaf Peter
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock85.027.27

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001919246Pelthos Therapeutics Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Channel Therapeutics Corp · former SEC name · 2024-11-18 to 2025-05-27
  • Chromocell Therapeutics Corp · former SEC name · 2022-09-06 to 2024-11-15

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$0$0

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗